Welcome to our dedicated page for ASEP MED HLDGS news (Ticker: SEPSF), a resource for investors and traders seeking the latest updates and insights on ASEP MED HLDGS stock.
ASEP MED HLDGS INC (SEPSF) delivers cutting-edge solutions for antibiotic-resistant infections through AI-powered diagnostics and therapeutic innovations. This news hub provides investors and medical professionals with essential updates on the company’s progress in combating sepsis and biofilm-related diseases.
Access official press releases covering regulatory milestones, clinical trial outcomes, and strategic partnerships. Our curated news collection enables stakeholders to track developments in three core areas: rapid sepsis detection systems, next-generation antimicrobial peptides, and infection-prevention medical coatings.
Stay informed about SEPSF’s advancements in artificial intelligence applications for gene expression analysis and peptide optimization. The page consolidates critical updates including FDA submissions, research collaborations, and intellectual property developments relevant to healthcare providers and biotech investors.
Bookmark this resource for real-time updates on technologies reshaping infection management. Visit regularly to monitor SEPSF’s progress in addressing the global antibiotic resistance crisis through measurable scientific breakthroughs.
Asep Medical Holdings Inc. (CSE: ASEP, OTCQB: SEPSF) announced a joint venture with Bahrain-based Seaspring W.L.L., marked by a Letter of Intent (LOI) signed on December 11, 2022. The partnership, which will see both companies owning 50% each, focuses on introducing Asep’s sepsis diagnostic technology in Bahrain and the broader MENA region. Seaspring will provide capital while Asep contributes licensing rights. Asep aims to address significant unmet medical needs related to antibiotic resistance and severe sepsis, which claims 11 million lives annually.
Asep Medical Holdings Inc. (CSE: ASEP, OTCQB: SEPSF) issued a clarification on its diagnostic and therapeutic technologies for sepsis and biofilm infections. With approximately 49 million sepsis cases globally annually, Asep's SepsetER assay offers a quicker diagnosis within 60-90 minutes, significantly faster than conventional methods. The company’s peptide technology aims to combat biofilm infections, which account for 65% of all infections. Asep is advancing its products towards FDA approval, with trials expected in mid-2023 and commercial sales projected for early 2024.
Asep Medical Holdings Inc. (OTCQB: SEPSF) announced advancements in combating antibiotic failure via its subsidiaries, Sepset Biosciences Inc. and ABT Innovations Inc. They developed a diagnostic assay, SepsetER, to detect severe sepsis in 60-90 minutes compared to conventional methods taking 8-36 hours. Additionally, a peptide technology targets biofilms, responsible for 65% of infections. Asep has secured over $20 million in funding from various organizations, positioning itself for significant market opportunities in healthcare.
Asep Medical Holdings Inc. (CSE: ASEP, OTCQB: SEPSF, FSE: JJ8) has announced the grant of 1,080,000 stock options to officers and advisors for recruitment and retention purposes. The options, exercisable at $0.30 per share, have various vesting schedules, with some vested immediately and others vesting over time until 2032. The company focuses on developing solutions for antibiotic failure and severe sepsis identification. Notably, their SepsetER test allows for rapid diagnosis, aiming to improve patient outcomes and address unmet medical needs.
Asep Medical Holdings Inc. (CSE: ASEP; OTCQB: SEPSF) announced that its sepsis diagnostic technology, SepsetER, has received patent approval in 13 European countries and Australia. This patent validates Asep's AI-based approach to diagnosing sepsis, which claims over 11 million lives annually. The test, developed under CEO Dr. Robert E. W. Hancock, enables rapid diagnosis with results in 60-90 minutes, significantly faster than existing methods. Asep is preparing for formal clinical studies aiming for FDA approval, potentially leading to marketing in emergency and intensive care settings.
Asep Medical Holdings Inc. has signed a Feasibility Study Agreement with Bohai Biomedical Technology Development Co. Ltd. for utilizing its proprietary anti-bacterial peptide in an oral rinse product aimed at preventing dental biofilm infections. The study will involve several thousand participants and leverage technology licensed from the University of British Columbia. The dental market is valued at USD $36.2 billion globally, with the Chinese market projected at USD $17 billion by 2026. Preliminary results have shown promise in combating difficult-to-treat oral infections.
Asep Medical Holdings Inc. announced the appointment of Jacqueline Tucker as Chief Financial Officer effective October 1, 2022. Tucker has extensive experience as a CFO in various public companies and replaces Jen Gretchen, who will continue as a consultant. The company expressed confidence in Tucker's leadership for its growth in the market. Asep focuses on combating antibiotic failure through proprietary diagnostics for severe sepsis and therapeutic agents addressing multidrug-resistant infections, which are critical to improving patient outcomes.
Asep Medical Holdings Inc. has appointed Dr. Richard Heinzl to its board of directors, effective immediately. Dr. Heinzl, a physician and entrepreneur, brings extensive experience in genomics and healthcare, having held roles including CEO of My Next Health Inc. and Global Medical Director at WorldCare Inc. His expertise is expected to enhance Asep's mission to tackle unmet medical needs related to antibiotic failure. The company focuses on developing diagnostic tools for severe sepsis and therapeutic agents for multidrug-resistant infections.
Asep Medical Holdings Inc. supports World Sepsis Day on September 13th, highlighting its commitment to combatting sepsis, a leading cause of morbidity and mortality. The company is developing a rapid test kit to identify severe sepsis, facilitating early treatment to improve patient outcomes. Asep Inc. announced a $1,000 donation to the Global Sepsis Alliance and is advancing its SepsetER test, which predicts severe sepsis using qPCR technology. Current diagnostic methods are often slow and inaccurate, underscoring the need for innovation in sepsis diagnostics.
Asep Medical Holdings Inc. has appointed Dr. Robert E. W. Hancock as CEO and Chairman, effective immediately, replacing Rudy Mazzocchi due to health issues. Dr. Hancock, co-founder and an expert in infectious diseases, has received numerous accolades for his research, including the Prix Galien and Killam Prize. He will also step down as COO, with Timothy Murphy, an experienced executive, taking over the role. Asep is focused on developing diagnostic tools and therapies for severe sepsis and multidrug-resistant infections, addressing significant unmet medical needs in these areas.
